30483-76-2

Upstream product

• 116922-22-6 3-morpholinonitrobenzene 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 30483-75-1 4-bromophenyl-morpholine 

Downstream Products

• 30483-77-3 4-[4-(2-bromo-phenylsulfanyl)-3-nitro-phenyl]-morpholine 
• 31618-93-6 N-[2-(2-bromo-phenylsulfanyl)-5-morpholin-4-yl-phenyl]-diacetamide 
• 31618-92-5 N-[2-(2-bromo-phenylsulfanyl)-5-morpholin-4-yl-phenyl]-acetamide 
• 30483-78-4 2-(2-bromo-phenylsulfanyl)-5-morpholin-4-yl-aniline 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.